Bio-Rad Laboratories, Inc. (FRA:BUWA)
| Market Cap | 7.41B |
| Revenue (ttm) | 2.18B |
| Net Income (ttm) | -576.07M |
| Shares Out | n/a |
| EPS (ttm) | -20.93 |
| PE Ratio | n/a |
| Forward PE | 30.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 277.20 |
| Previous Close | 278.50 |
| Day's Range | 277.20 - 277.20 |
| 52-Week Range | 187.35 - 349.10 |
| Beta | n/a |
| RSI | 53.75 |
| Earnings Date | Feb 13, 2026 |
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science e... [Read more]
Financial Performance
In 2024, Bio-Rad Laboratories's revenue was $2.57 billion, a decrease of -3.92% compared to the previous year's $2.67 billion. Losses were -$1.84 billion, 189.4% more than in 2023.
Financial numbers in USD Financial StatementsNews
Citigroup Raises Price Target for Bio-Rad Laboratories (BIO) to $375 | BIO Stock News
Citigroup Raises Price Target for Bio-Rad Laboratories (BIO) to $375 | BIO Stock News
Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday
The company doesn't seem like it will generate pops in key fundamentals anytime soon.
Bio-Rad Laboratories Inc (BIO) Q3 2025 Earnings Call Highlights: Navigating Challenges with ...
Bio-Rad Laboratories Inc (BIO) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Laboratories Inc (BIO)
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Laboratories Inc (BIO)
Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
Bio-Rad Laboratories Inc (BIO) Q3 Earnings: Revenue Surpasses Estimates at $653M, Non-GAAP EPS ...
Bio-Rad Laboratories Inc (BIO) Q3 Earnings: Revenue Surpasses Estimates at $653M, Non-GAAP EPS Falls Short at $2.26
Bio-Rad Laboratories, Inc. Non-GAAP EPS of $2.26 beats by $0.33, revenue of $653M beats by $1.7M
Bio-Rad Reports Third-Quarter 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
What to Expect from Bio-Rad Laboratories Inc (BIO) Q3 2025 Earnings
What to Expect from Bio-Rad Laboratories Inc (BIO) Q3 2025 Earnings
Ariel Focus Fund buys AJG, PBH and FI; exits ZIMV, CLB and BIO
Compelling Value In Small-Cap Equities And Select Cyclicals
Supplier of residential thermal, comfort and security solutions, Resideo Technologies, Inc. (REZI) was the top contributor in the quarter. Shares of gold mining company, Barrick Mining Corporation (B)...
7 Stocks Taking The Next Step To Be On Offense
Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens ...
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays
Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX...
It's time to scoop up undervalued stocks in this critical sector of the economy
Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.
PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidi...
Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Bio-Rad Laboratories, Inc. (NYSE:BIO) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chai...
Bio-Rad's Management to Participate in Upcoming Investor Conferences
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the com...
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth fo...
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's mana...
Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Jonathan P. DiVincenzo - President & COO Norman D.
Bio-Rad Reports Second-Quarter 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Raja...
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...